Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 124

    2.

    A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.

    Gershonov E, Goldwaser I, Fridkin M, Shechter Y.

    J Med Chem. 2000 Jun 29;43(13):2530-7.PMID: 10891112 [PubMed - indexed for MEDLINE]Related articles

    3.

    Reversible pegylation of insulin facilitates its prolonged action in vivo.

    Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, Fridkin M.

    Eur J Pharm Biopharm. 2008 Sep;70(1):19-28. Epub 2008 Apr 7.PMID: 18495444 [PubMed - indexed for MEDLINE]Related articles

    4.

    Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin.

    Shechter Y, Mironchik M, Rubinraut S, Saul A, Tsubery H, Fridkin M.

    Bioconjug Chem. 2005 Jul-Aug;16(4):913-20.PMID: 16029032 [PubMed - indexed for MEDLINE]Related articles

    6.

    Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats.

    Shechter Y, Tsubery H, Fridkin M.

    Biochem Biophys Res Commun. 2003 Jul 25;307(2):315-21.PMID: 12859957 [PubMed - indexed for MEDLINE]Related articles

    7.

    Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.

    Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M.

    Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1212-7.PMID: 11158619 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment.

    Wan CK, Giacca A, Matsuhisa M, El-Bahrani B, Lam L, Rodgers C, Shi ZQ.

    Metabolism. 2000 Aug;49(8):984-9.PMID: 10954014 [PubMed - indexed for MEDLINE]Related articles

    9.

    Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide.

    Nesher M, Vachutinsky Y, Fridkin G, Schwarz Y, Sasson K, Fridkin M, Shechter Y, Lichtstein D.

    Bioconjug Chem. 2008 Jan;19(1):342-8. Epub 2007 Dec 11.PMID: 18069777 [PubMed - indexed for MEDLINE]Related articles

    10.

    Blood glucose profiles in diabetic rodents using different insulin preparations.

    Schneider S, Weber R, Luippold G.

    Arzneimittelforschung. 2004;54(12):842-6.PMID: 15646368 [PubMed - indexed for MEDLINE]Related articles

    11.

    [2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.

    Shechter Y, Tsubery H, Fridkin M.

    Biochem Biophys Res Commun. 2003 May 30;305(2):386-91.PMID: 12745087 [PubMed - indexed for MEDLINE]Related articles

    12.

    Hypoglycemic effect of Hypoxis hemerocallidea corm (African potato) aqueous extract in rats.

    Mahomed IM, Ojewole JA.

    Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):617-23.PMID: 14671679 [PubMed - indexed for MEDLINE]Related articles

    13.

    Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats.

    Xia CQ, Wang J, Shen WC.

    J Pharmacol Exp Ther. 2000 Nov;295(2):594-600.PMID: 11046093 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Controlled release of insulin from pH/temperature-sensitive injectable pentablock copolymer hydrogel.

    Huynh DP, Im GJ, Chae SY, Lee KC, Lee DS.

    J Control Release. 2009 Jul 1;137(1):20-4. Epub 2009 Mar 12.PMID: 19285530 [PubMed - indexed for MEDLINE]Related articles

    15.

    N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C(1) is a long-acting prodrug derivative.

    Shechter Y, Tsubery H, Fridkin M.

    J Med Chem. 2002 Sep 12;45(19):4264-70.PMID: 12213067 [PubMed - indexed for MEDLINE]Related articles

    16.

    [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]

    Ozawa H, Murai Y, Ozawa T.

    Yakushigaku Zasshi. 2003;38(1):11-27. Japanese. PMID: 14570054 [PubMed - indexed for MEDLINE]Related articles

    17.

    Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study.

    Paul W, Sharma CP.

    J Pharm Sci. 2008 Feb;97(2):875-82.PMID: 17497735 [PubMed - indexed for MEDLINE]Related articles

    18.
    19.

    Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

    Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

    20.

    Biological activity of AC3174, a peptide analog of exendin-4.

    Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.

    Regul Pept. 2007 Jun 7;141(1-3):113-9. Epub 2007 Jan 11.PMID: 17292977 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data